Compare CAC & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAC | ZVRA |
|---|---|---|
| Founded | 1875 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 923.2M | 741.9M |
| IPO Year | 1996 | 2015 |
| Metric | CAC | ZVRA |
|---|---|---|
| Price | $54.14 | $14.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $47.00 | $23.00 |
| AVG Volume (30 Days) | 107.2K | ★ 1.7M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | 6.08 | ★ 159.21 |
| EPS | ★ 1.29 | 0.60 |
| Revenue | $41,739,000.00 | ★ $106,470,000.00 |
| Revenue This Year | $19.15 | $37.27 |
| Revenue Next Year | $6.05 | $53.42 |
| P/E Ratio | $41.81 | ★ $23.60 |
| Revenue Growth | 16.96 | ★ 350.91 |
| 52 Week Low | $35.00 | $7.16 |
| 52 Week High | $56.23 | $14.58 |
| Indicator | CAC | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 53.81 | 70.27 |
| Support Level | $46.61 | $8.26 |
| Resistance Level | $53.64 | N/A |
| Average True Range (ATR) | 1.62 | 0.58 |
| MACD | -0.03 | 0.06 |
| Stochastic Oscillator | 56.37 | 98.46 |
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.